| Protocol |
Title |
Status |
Contact |
| 103683 |
GOG-3076 a Phase 3 Trial in Platinum-Resistant/Refractory Ovarian Cancer |
OPEN TO ACCRUAL |
 |
| 103743 |
A Phase 1b Dose Escalation Study of AV-380 in Combination with Chemotherapy or Immunotherapy in Cancer Patients with Elevated GDF-15 Levels Colorectal Cancer, NSCLC, Pancreatic Cancer |
OPEN TO ACCRUAL |
|
| 103747 |
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal
Carcinoma |
OPEN TO ACCRUAL |
|
| 103984 |
OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy |
OPEN TO ACCRUAL |
|
| 104019 |
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer |
OPEN TO ACCRUAL |
|
| 103792 |
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868) |
OPEN TO ACCRUAL |
|
| 103952 |
Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma |
OPEN TO ACCRUAL |
|
| 103704 |
A Phase 1/2 Open label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) |
OPEN TO ACCRUAL |
|
| 103921 |
AHOD2131 - A Randomized, Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and Stage II Classic Hodgkin Lymphoma |
OPEN TO ACCRUAL |
|
| 103945 |
A Phase 2, Randomized Study to Evaluate the Safety, Efficacy and Optimal dose of ABBV-400 in Combination with Fluorouracil (5-FU), Folinic Acid and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer (mCRC) |
OPEN TO ACCRUAL |
|
| 103849 |
Feasibility Study- ReVeal FGS 475 System for Bevonescein-Assisted Intra-Operative Visualization of Nerves in Head and Neck Surgery |
OPEN TO ACCRUAL |
|
| 103819 |
A Phase III, Single Arm Study to Evaluate the Efficacy and Safety of ONCOFID P B (paclitaxel hyaluronic acid conjugate) Administered Intravesically to Patients with BCG unresponsive Carcinoma in Situ of the Bladder with or without Ta T1 Papillary Disease |
OPEN TO ACCRUAL |
|
| 103669 |
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA Positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer |
OPEN TO ACCRUAL |
|
| 103080 |
INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature Driven Analysis |
OPEN TO ACCRUAL |
|
| 103759 |
A Phase III, Multicenter, Open label Study of Ribociclib vs. Palbociclib in Patients With Advanced Hormone Receptor positive/HER2 negative/HER2 Enriched Breast Cancer HARMONIA Trial |
OPEN TO ACCRUAL |
|
| 103727 |
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma |
OPEN TO ACCRUAL |
|
| 103351 |
A Phase 1b Dose Escalation Study Of Metabolically Fit Cd19 Chimeric Antigen Receptor (Car) T Cells With Cd34 Selection Markers In Adult Patients With Relapsed Or Refractory Cd19 B Cell Non Hodgkin Lymphoma And Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
OPEN TO ACCRUAL |
|
| 103717 |
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor (Endometrial cohort enrolling 2nd and 3rd line patients.) |
OPEN TO ACCRUAL |
|
| 103253 |
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma |
OPEN TO ACCRUAL |
|
| 103810 |
A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody Drug Conjugate MYTX 011 in Subjects with Non Small Cell Lung Cancer |
OPEN TO ACCRUAL |
|